PolyMedix, Inc. (OTC: PYMX) soared 19.86% to $0.700 in the early hours after the company announced that an interim analysis of results from more than 80 patients enrolled in its Phase 2 clinical trial with PMX-30063 defensin-mimetic antibiotic, indicate that all dosing arms in the study were both safe and effective in treating patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by S. aureus.
This is the first ever patient clinical efficacy study conducted with this new defensin-mimetic antibiotic class. PolyMedix is continuing to enroll patients and expects to complete the full trial in the first half of 2012.
PolyMedix, Inc. is a biotechnology company focused on treating acute cardiovascular disorders and life threatening, serious, infectious diseases with small synthetic molecule compounds that mimic the activity of large natural protein molecules, compounds referred to as biomimetics.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.